The biochip industry is in the early stages of growth and hence, not only promises potential but also is susceptible to vagaries of market forces. Competition, patent disputes, knowledge constraints (in terms of skilled employees, technical know-how) and financial strength might be a few impediments for firms engaged in this industry. A promising market arises from three factors - an aging population, third party reimbursement and a growing number of individuals suffering from common chronic diseases. Gene expression profiling will continue to be the leading application of biochips. Biochips would certainly evolve in terms of physical and technical characteristics. Following the focus on miniaturization of assays, they would turn smaller and more powerful with each generation.
The biochip industry is characterized by both intense rivalry and an equally well-developed web of alliances. There are numerous smaller companies and hence it is no surprise that the bigger companies are able to buy their way into the market. Companies currently compete within narrow confines of genomic demand and technological prowess. Leading players operating in the biochips market include Affymetrix, Applied Biosystems Group, Biomerieux, Bio-Rad Laboratories, Inc., Caliper Life Sciences, Inc., Cepheid Inc., GE Healthcare Ltd., Takara Bio, Inc., and Zyomyx.
The report titled "Biochips: A Global Strategic Business Report" published by Global Industry Analysts, Inc., captures latest market trends, issues and technology advancements of the US, Canada, Japan, Europe (France, Germany, United Kingdom, and Rest of Europe), and Rest of World. The report further provides a brief insight into the competitive scenario, product and technology trends, new product innovations and developments and recent strategic corporate developments.
For more details about t
Copyright©2008 Vocus, Inc.
All rights reserved